A+ A-

 

Problem drug use prevalence in France – 2006 estimations

 

epfajcq5.gif

OFDT, 30 p., May 2010

Problem Drug Use is one of the EMCCDDA five key indicators.
It is defined as "injecting drug use or long duration/regular use of opioids, cocaine and/or amphetamines" for the 15-64 year old age group.
This OFDT work provides a new estimate for France following the estimates previously produced in 1995 and 1999. This new estimate, between 210,000 and 250,000 problem drug users (central estimation 230,000) is based on data from 2006 and different methods.
This document also provides an estimate of the number of regular heroin users (75,000) and injecting drug users (81,000).

Authors :
Jean-Michel Costes, Laure Vaissade, Emanuella Colasante*, Christophe Palle, Stéphane Legleye, Eric Janssen, Abdalla Toufik, Agnès Cadet-Taïrou
* Consiglio Nazionale delle Ricerche, Instituto di Fisiologia Clinica,Rome, Italie

Download the PDF file (159 Ko)

 

 

 

 

 

 

 

 

 

 

 

 

Drugs in Europe


2023 EMCDDA European Drug Report

The European Drug Report 2023: Trends and Developments presents the EMCDDA’s latest analysis of the drug situation in Europe. Focusing on illicit drug use, related harms and drug supply, the report contains a comprehensive set of national data across these themes and key harm-reduction interventions. This report is based on information provided to the EMCDDA by the EU Member States, the candidate country Türkiye, and Norway, in an annual reporting process.

  Statistical Bulletin 2023

The annual Statistical Bulletin contains the most recent available data on the drug situation in Europe provided by the Member States. These datasets underpin the analysis presented in the European Drug Report. All data may be viewed interactively on screen and downloaded in Excel format.

The European Union and the drug phenomenon

miniFAQDrugsEurope.jpgThe European Union & the drug phenomenon : Frequently asked questions, joint publication between the EMCDDA and the European Commission, october 2010, 12 p.